Literature DB >> 8530023

Sequences promoting the transcription of the human XA gene overlapping P450c21A correctly predict the presence of a novel, adrenal-specific, truncated form of tenascin-X.

M K Tee1, A A Thomson, J Bristow, W L Miller.   

Abstract

A compact region in the human class III major histocompatibility locus contains the human genes for the fourth component of human complement (C4) and steroid 21-hydroxylase (P450c21) in one transcriptional orientation, while the gene for the extracellular matrix protein tenascin-X (TN-X) overlaps the last exon of P450c21 on the opposite strand of DNA in the opposite transcriptional orientation. This complex locus is duplicated into A and B loci, so that the organization is 5'-C4A-21A-XA-C4B-21B-XB-3'. Although this duplication event truncated the 65-kb X(B) gene to a 4.5-kb XA gene, the XA gene is transcriptionally active in the adrenal cortex. To examine the basis of the tissue-specific expression of XA and C4B, we cloned the 1763-bp region that lies between the cap sites for XA and C4B and analyzed its promoter activity in both the XA and the C4 orientations. Powerful, liver-specific sequences lie within the first 75 to 138 bp from the C4B cap site, and weaker elements lie within 128 bp of the XA cap site that function in both liver and adrenal cells. Because these 128 bp upstream from the XA cap site are perfectly preserved in the XB gene encoding TN-X, we sought to determine whether a transcript similar to XA arises within the XB gene. RNase protection assays, cDNA cloning, and RT/PCR show that adrenal cells contain a novel transcript, termed short XB (XB-S), which has the same open reading frame as TN-X.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530023     DOI: 10.1006/geno.1995.1128

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  9 in total

Review 1.  Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome.

Authors:  Walter L Miller; Deborah P Merke
Journal:  Horm Res Paediatr       Date:  2018-05-07       Impact factor: 2.852

Review 2.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

Review 3.  Molecular aspects of melanocytic dysplastic nevi.

Authors:  Mahmoud Rezk Abd-Elwahed Hussein; Gary Stewart Wood
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

4.  Application of three different methods to analyse fibre-FISH results obtained using four lambda clones from the porcine MHC III region.

Authors:  A Sjöberg; L J Peelman; B P Chowdhary
Journal:  Chromosome Res       Date:  1997-06       Impact factor: 5.239

5.  Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms.

Authors:  Meng Kian Tee; Ningwu Huang; Izabella Damm; Walter L Miller
Journal:  Mol Endocrinol       Date:  2011-03-10

6.  Great genotypic and phenotypic diversities associated with copy-number variations of complement C4 and RP-C4-CYP21-TNX (RCCX) modules: a comparison of Asian-Indian and European American populations.

Authors:  Kapil Saxena; Kathryn J Kitzmiller; Yee Ling Wu; Bi Zhou; Nazreen Esack; Leena Hiremath; Erwin K Chung; Yan Yang; C Yung Yu
Journal:  Mol Immunol       Date:  2009-01-09       Impact factor: 4.407

7.  Truncated form of tenascin-X, XB-S, interacts with mitotic motor kinesin Eg5.

Authors:  Toshiya Endo; Hiroyoshi Ariga; Ken-ichi Matsumoto
Journal:  Mol Cell Biochem       Date:  2008-08-05       Impact factor: 3.842

8.  Tenascin-X-Discovery and Early Research.

Authors:  Walter L Miller
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

9.  Recurrent pneumothorax in a case of tenascin-X deficient Ehlers-Danlos syndrome: Broadening the phenotypic spectrum.

Authors:  Renee Santoreneos; Cassandra Vakulin; Melissa Ellul; Lesley Rawlings; Tristan Hardy; Nicola Poplawski
Journal:  Am J Med Genet A       Date:  2022-02-06       Impact factor: 2.578

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.